TY - JOUR AU - Imre, Gergely AU - Takács, Bertalan Vilmos AU - Czipa, Erik AU - Drubi, Andrea AU - Jaksa, Gábor AU - Latinovics, Dóra AU - Nagy, Andrea AU - Karkas, Réka AU - Hudoba, Liza AU - Vásárhelyi, Bálint Márk AU - Pankotai-Bodó, Gabriella AU - Blastyák, András AU - Hegedűs, Zoltán AU - Germán, Péter AU - Bálint, Balázs AU - Ahmed Abdullah, Khaldoon Sadiq AU - Kopasz, Anna Georgina AU - Kovács, Anita Kármen AU - Nagy, László AU - Sükösd, Farkas AU - Pintér, Lajos AU - Rülicke, Thomas AU - Barta, Endre AU - Nagy, István AU - Haracska, Lajos AU - Mátés, Lajos TI - Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy JF - MOLECULAR THERAPY-METHODS AND CLINICAL DEVELOPMENT J2 - MOL THER-METH CLIN D VL - 29 PY - 2023 SP - 145 EP - 159 PG - 15 SN - 2329-0501 DO - 10.1016/j.omtm.2023.03.003 UR - https://m2.mtmt.hu/api/publication/33708483 ID - 33708483 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Anita Kármen AU - Atlasz, Tamás AU - Werling, Dóra AU - Szabó, Edina AU - Reglődi, Dóra AU - Tóth, Gábor TI - Stability Test of PACAP in Eye Drops JF - JOURNAL OF MOLECULAR NEUROSCIENCE J2 - J MOL NEUROSCI VL - 71 PY - 2021 IS - 8 SP - 1567 EP - 1574 PG - 8 SN - 0895-8696 DO - 10.1007/s12031-020-01532-9 UR - https://m2.mtmt.hu/api/publication/31288128 ID - 31288128 N1 - Funding Agency and Grant Number: Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary of the FIKPII; Centre for Neuroscience; PTE AOK Research Grant [KA-2017-15]; PTE AOK-TANDEM 2019 Grant, "The role of neuro-inflammation in neurodegeneration: from molecules to clinics"; [NAP 2017-1.2.1-NKP-2017-00002]; [NKFIH129190]; [GINOP-2.3.2-15-2016-00050]; [MTA-TKI 14016]; [EFOP-3.6.2-16-2017-00008]; [EFOP 3.6.1-16.2016.00004]; [UNKP-19-3-III-PTE-127]; [UNKP-19-3-1-PTE-137]; [UNKP-18-4-1-PTE-364]; [UNKP-16-4-IV]; [TUDFO/47138-1/2019-ITM FIKP] Funding text: This work was supported by the following grants: NAP 2017-1.2.1-NKP-2017-00002, NKFIH129190, Bolyai Scholarship, GINOP-2.3.2-15-2016-00050 "PEPSYS", MTA-TKI 14016, EFOP-3.6.2-16-2017-00008, EFOP 3.6.1-16.2016.00004, UNKP-19-3-III-PTE-127, UNKP-19-3-1-PTE-137, UNKP-18-4-1-PTE-364, UNKP-16-4-IV, Centre for Neuroscience, PTE AOK Research Grant KA-2017-15, PTE AOK-TANDEM 2019 Grant, "The role of neuro-inflammation in neurodegeneration: from molecules to clinics"; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the FIKPII; TUDFO/47138-1/2019-ITM FIKP program. AB - PACAP is a neuropeptide with widespread distribution and diverse biological functions. It has strong cytoprotective effects mediated mainly through specific PAC1 receptors. Experimental data show protective effects of PACAP in the retina and cornea in several pathological conditions. Although intravitreal injections are a common practice in some ocular diseases, delivery of therapeutic agents in the form of eye drops would be more convenient and would lead to fewer side effects. We have previously shown that PACAP, in the form of eye drops, is able to pass through the ocular barriers and can exert retinoprotective effects. As eye drops represent a promising form of administration of PACAP in ocular diseases, it is important to investigate the stability of PACAP in solutions used in eye drops. In this study, the stability of PACAP1-27 and PACAP1-38 in eye drops was measured in four common media and a commercially available artificial tear solution at both room temperature and +4 °C. Mass spectrometry results show that the highest stability was gained with PACAP1-38 in water and 0.9% saline solution at +4 °C, representing 80–90% drug persistence after 2 weeks. PACAP1-38 in the artificial tear showed very fast degradation at room temperature, but was stable at +4 °C. In summary, PACAP1-38 has higher stability than PACAP1-27, with highest stability at +4 °C in water solution, but both peptides in each medium can be stored for relatively longer periods without significant degradation. These data can provide reference for future therapeutic use of PACAP in eye drops. LA - English DB - MTMT ER - TY - JOUR AU - Kotogány, Edit AU - Balog, József Ágoston AU - Nagy, Lajos I. AU - Alföldi, Róbert AU - Bertagnolo, Valeria AU - Brugnoli, Federica AU - Demjén, András AU - Kovács, Anita Kármen AU - Batár, Péter AU - Mezei, Gabriella AU - Szabó, Renáta AU - Kanizsai, Iván AU - Varga, Csaba AU - Puskás, László AU - Szebeni, Gábor TI - Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 21 PY - 2020 IS - 14 PG - 27 SN - 1661-6596 DO - 10.3390/ijms21145135 UR - https://m2.mtmt.hu/api/publication/31385279 ID - 31385279 N1 - Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 29 August 2020 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Avidin Ltd., Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, UNKP-19-4-SZTE-36, BO/00139/17/8 Funding text 1: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 10 January 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Avidin Ltd., Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, UNKP-19-4-SZTE-36, BO/00139/17/8 Funding details: Ministry for Innovation and Technology Funding details: National Research, Development and Innovation Office Funding text 1: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 10 February 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Avidin Ltd., Alsó kikötő sor 11/D, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Department of Physiology, Közép fasor 52, Hungary; email: szebeni.gabor@brc.hu Funding Agency and Grant Number: National Research, Development and Innovation Office, Hungary [GINOP-2.3.2-15-2016-00001, GINOP-2.3.2-15-2016-00030]; Janos Bolyai Research Scholarship of the Hungarian Academy of SciencesHungarian Academy of Sciences [BO/00139/17/8]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-19-4-SZTE-36] Funding text: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gabor J. Szebeni was supported by Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 12 March 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Avidin Ltd., Alsó kikötő sor 11/D, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Department of Physiology, Közép fasor 52, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, BO/00139/17/8, UNKP-19-4-SZTE-36 Funding details: Ministry for Innovation and Technology Funding details: National Research, Development and Innovation Office Funding text 1: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; G?bor J. Szebeni was supported by J?nos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Funding text 2: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. LA - English DB - MTMT ER - TY - JOUR AU - Balog, József Ágoston AU - Hackler, László AU - Kovács, Anita Kármen AU - Neuperger, Patricia AU - Alföldi, Róbert AU - Nagy, Lajos István AU - Puskás, László AU - Szebeni, Gábor TI - Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model. JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 21 PY - 2020 IS - 1 SN - 1661-6596 DO - 10.3390/ijms21010170 UR - https://m2.mtmt.hu/api/publication/31143380 ID - 31143380 N1 - Laboratory of Functional Genomics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary AstridBio Technologies Ltd., Also kikötő sor 11/D, Szeged, H6726, Hungary Avidin Ltd., Also kikötő sor 11/D, Szeged, H6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 30 January 2020 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Biological Research Centre, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Laboratory of Functional Genomics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary AstridBio Technologies Ltd., Also kikötő sor 11/D, Szeged, H6726, Hungary Avidin Ltd., Also kikötő sor 11/D, Szeged, H6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Cited By :3 Export Date: 10 February 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu AB - The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in the immunotherapy regimens. Here, we addressed the multidimensional immunophenotyping of 4T1 metastatic breast cancer by the state-of-the-art single cell mass cytometry (CyTOF). We determined the dose and time dependent cytotoxicity of cisplatin on 4T1 cells by the xCelligence real-time electronic sensing assay. Cisplatin treatment reduced tumor growth, number of lung metastasis, and the splenomegaly of 4T1 tumor bearing mice. We showed that cisplatin inhibited the tumor stroma formation, the polarization of carcinoma-associated fibroblasts by the diminished proteolytic activity of fibroblast activating protein. The CyTOF analysis revealed the emergence of CD11b+/Gr-1+/CD44+ or CD11b+/Gr-1+/IL-17A+ myeloid-derived suppressor cells (MDSCs) and the absence of B220+ or CD62L+ B-cells, the CD62L+/CD4+ and CD62L+/CD8+ T-cells in the spleen of advanced cancer. We could show the immunomodulatory effect of cisplatin via the suppression of splenic MDSCs and via the promotion of peripheral IFN-γ+ myeloid cells. Our data could support the use of low dose chemotherapy with cisplatin as an immunomodulatory agent for metastatic triple negative breast cancer. LA - English DB - MTMT ER - TY - THES AU - Kovács, Anita Kármen TI - Optimized synthesis routes and biological application of N-peptide-6-amino-D-luciferin conjugates PB - Szegedi Tudományegyetem (SZTE) PY - 2019 SP - 116 DO - 10.14232/phd.10082 UR - https://m2.mtmt.hu/api/publication/30806726 ID - 30806726 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Anita Kármen AU - Hegyes, P. AU - Szebeni, Gábor AU - Bogár, K. AU - Puskás, László AU - Tóth, Gábor TI - Synthesis of N-Peptide-6-Amino-d-Luciferin Conjugates with Optimized Fragment Condensation Strategy JF - INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS J2 - INT J PEPT RES THER VL - 25 PY - 2019 IS - 3 SP - 1209 EP - 1215 PG - 7 SN - 1573-3149 DO - 10.1007/s10989-018-9768-8 UR - https://m2.mtmt.hu/api/publication/30382079 ID - 30382079 N1 - Department of Medical Chemistry, University of Szeged, Dóm tér 8., Szeged, 6720, Hungary Avidin Ltd, Alsó Kikötő sor 11/D., Szeged, 6726, Hungary Biological Research Center, Hungarian Academy of Sciences, Temesvári krt. 62., Szeged, 6726, Hungary Institute of Pharmaceutical Analysis, University of Szeged, Somogyi u. 4., Szeged, 6720, Hungary Export Date: 9 January 2019 Article in Press CODEN: IJPRF Correspondence Address: Kovács, A.K.; Avidin Ltd, Alsó Kikötő sor 11/D., Hungary; email: kovacs.anita@med.u-szeged.hu AB - Abstract: The synthesis of peptide-luciferin conjugates has a pivotal role in the development of bioluminescent detection systems that are based on the determination of protease enzyme activity. This work describes the optimized synthesis of an N-peptide-6-amino-d-luciferin conjugate (Fmoc-Gly-Pro-6-amino-d-luciferin) with a simple fragment condensation method in adequate yields. Fmoc-Gly-Pro-6-amino-d-luciferin was produced from a previously synthesized Fmoc-Gly-Pro-OH and also previously synthesized 6-amino-2-cyanobenzothiazole with an optimized method, to which conjugate cysteine was added in an also improved way. The resulting conjugate was successfully used in a bioluminescent system, in vitro, demonstrating the applicability of the method. Graphical Abstract: [Figure not available: see fulltext.]. © 2018, Springer Nature B.V. LA - English DB - MTMT ER - TY - JOUR AU - Angyal, Anikó AU - Demjén, András AU - Wéber, Edit AU - Kovács, Anita Kármen AU - Wölfling, János AU - Puskás, László AU - Kanizsai, Iván TI - Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullie-Ugi Three-Component Reaction JF - JOURNAL OF ORGANIC CHEMISTRY J2 - J ORG CHEM VL - 83 PY - 2018 IS - 7 SP - 3570 EP - 3581 PG - 12 SN - 0022-3263 DO - 10.1021/acs.joc.7b03189 UR - https://m2.mtmt.hu/api/publication/3389411 ID - 3389411 AB - A ZnCl2-catalyzed diastereoselective Joullie Ugi three-component reaction from 2H-azirines, isocyanides, and carboxylic acids was established. The protocol allows the preparation of highly and diversely functionalized N-acylaziridine-2-carboxamide derivatives in up to 82% isolated yields. Moreover, the applicability of N-acylaziridines is demonstrated through a variety of transformations. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Anita Kármen AU - Hegyes, Péter AU - Szebeni, Gábor AU - Nagy, Lajos I AU - Puskás, László AU - Tóth, Gábor TI - Synthesis of N-peptide-6-amino-D-luciferin Conjugates JF - FRONTIERS IN CHEMISTRY J2 - FRONT CHEM VL - 6 PY - 2018 PG - 11 SN - 2296-2646 DO - 10.3389/fchem.2018.00120 UR - https://m2.mtmt.hu/api/publication/3361945 ID - 3361945 N1 - Department of Medical Chemistry, University of Szeged, Szeged, Hungary Avidin Ltd., Szeged, Hungary Department of Genetics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary Cited By :2 Export Date: 21 January 2021 Correspondence Address: Kovács, A.K.; Department of Medical Chemistry, Hungary; email: kovacs.anita@med.u-szeged.hu AB - A general strategy for the synthesis of N-peptide-6-amino-D-luciferin conjugates has been developed. The applicability of the strategy was demonstrated with the preparation of a known substrate, N-Z-Asp-Glu-Val-Asp-6-amino-D-luciferin (N-Z-DEVD-aLuc). N-Z-DEVD-aLuc was obtained via a hybrid liquid/solid phase synthesis method, in which the appropriately protected C-terminal amino acid was coupled to 6-amino-2-cyanobenzothiazole and the resulting conjugate was reacted with D-cysteine in order to get the protected amino acid-6-amino-D-luciferin conjugate, which was then attached to resin. The resulting loaded resin was used for the solid-phase synthesis of the desired N-peptide-6-amino-D-luciferin conjugate without difficulties, which was then attested with NMR spectroscopy and LC-MS, and successfully tested in a bioluminescent system. LA - English DB - MTMT ER - TY - CONF AU - Kovács, Anita Kármen AU - Hagyes, P AU - Szebeni, Gábor AU - Puskas, LG AU - Toth, GK TI - Comparison of Fmoc-, Boc- and fragment condensation strategies in the synthesis of peptide-6-amino-D-luciferin conjugates T2 - 12th Australian Peptide Conference PY - 2017 SP - 89 UR - https://m2.mtmt.hu/api/publication/3284935 ID - 3284935 LA - English DB - MTMT ER - TY - CONF AU - Kovács, Anita Kármen AU - Hegyes, P AU - Szebeni, Gábor AU - Puskas, LG AU - Toth, GK TI - Novel synthesis methods of peptide-t-amino-D-luciferin conjugates for protease activity detection T2 - 23rd Young Research Fellow Meeting PY - 2016 PG - 1 UR - https://m2.mtmt.hu/api/publication/3184498 ID - 3184498 LA - English DB - MTMT ER -